Full Press Release Details
Media
• May 1, 2024
IRWD Positive Sentiment
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
Key Takeaway: Ironwood Pharmaceuticals announced that it will present new data on its once-weekly apraglutide treatment for Short Bowel Syndrome with Intestinal Failure at the upcoming Digestive Disease Week 2024. This presentation highlights the company's commitment to addressing this challenging condition. The event is anticipated to draw significant attention within the medical community.
Price reaction · baseline $7.75 (2024-04-30 close) · hit after-hours · 1 other IRWD headline(s) in the window, move may be shared
day 0 close
+6.1%
day 1 · peak
+7.1%
day 3
+4.6%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals is presenting new data on apraglutide.
- The presentation will occur at a significant event, Digestive Disease Week 2024.
- The focus is on a treatment for Short Bowel Syndrome with Intestinal Failure.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is apraglutide used for?
Apraglutide is used for treating Short Bowel Syndrome with Intestinal Failure.
When will Ironwood present new data on apraglutide?
Ironwood will present new data at Digestive Disease Week 2024.
What event will feature Ironwood's new data?
The new data will be presented at Digestive Disease Week 2024.
What condition does apraglutide target?
Apraglutide targets Short Bowel Syndrome with Intestinal Failure.